Vibegron is a selective b 3 -adrenergic receptor agonist in development for overactive bladder (OAB). Approximately 43% of patients on any OAB medication are taking a drug metabolized through the CYP2D6 pathway. In vitro data (human liver microsomal incubations and hepatocyte cultures) demonstrate that vibegron at concentrations up to 100 mM does not inhibit human cytochrome P450 (CYP) enzymes CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Two clinical studies were conducted to evaluate the pharmacokinetic, safety, and tolerability effects of vibegron on the CYP2D6 substrates tolterodine and metoprolol in healthy volunteers.
INTRODUCTION AND OBJECTIVES:
Vibegron is a selective b 3 -adrenergic receptor agonist in development for overactive bladder (OAB) . Approximately 43% of patients on any OAB medication are taking a drug metabolized through the CYP2D6 pathway. In vitro data (human liver microsomal incubations and hepatocyte cultures) demonstrate that vibegron at concentrations up to 100 mM does not inhibit human cytochrome P450 (CYP) enzymes CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Two clinical studies were conducted to evaluate the pharmacokinetic, safety, and tolerability effects of vibegron on the CYP2D6 substrates tolterodine and metoprolol in healthy volunteers.
METHODS: Two phase-1, single-center, open-label studies enrolled healthy volunteers to receive multiple-dose tolterodine extended release (ER) 4 mg with and/or without multiple doses of vibegron 100 mg (n[12), or single-dose metoprolol succinate 100 mg with and without multiple-dose vibegron 75 mg (n[24) . Pharmacokinetic parameters were calculated to evaluate tolterodine or metoprolol alone and in combination with steady-state vibegron. Safety and tolerability were assessed throughout the study.
RESULTS: Coadministration of vibegron did not alter the geometric mean maximum plasma concentration (Cmax) and the area under the curve (AUC) of tolterodine (geometric mean ratio [90% confidence intervals], 1.12 [1.00, 1.26] and 1.08 [0.97, 1.21]), respectively. The elimination half-life of tolterodine was similar alone and in the presence of steady-state vibegron (9.34 hr alone vs 9.48 hr in combination). Metoprolol geometric mean Cmax and AUC values increased slightly in the presence of vibegron by 49% (1.49 [1.35-1.65]) and 40% (1.40 [1.30-1.52]) respectively. However, the elimination half-life of metoprolol was similar alone and with vibegron (9.49 hr alone vs 10.88 hr in combination), suggesting CYP2D6 was unlikely inhibited. Study treatments were well tolerated, with no evidence of increased rates of adverse events during combination administration with vibegron.
CONCLUSIONS: Clinically significant drug-drug interactions (DDI) do not occur when vibegron is administered with tolterodine or metoprolol. In total, the in vitro and clinical data demonstrate that vibegron does not inhibit CYP2D6 and has a favorable DDI profile for use in patients with OAB. However, concerns have emerged about side effects of antimuscarinics in central nervous system (CNS). The aim of this study is to investigate the bladder selectivity of DA-8010, a novel antimuscarinic agent being developed for the treatment of OAB, over the brain in mice.
METHODS: Carbachol-induced intravesical pressure (IVP) elevation was measured in female ICR mice administered intravenously at 5 min or orally at each time points (1, 2, 6, 12 and 24 h) with antimuscarinics prior to treatment of carbachol. Dynamic [11C](þ)3-MPB PET studies were performed in mice intravenously administered with antimuscarinics, and regional brain non-displaceable binding potential of [11C](þ)3-MPB to muscarinic receptors was calculated compared to control. The Y-maze test was conducted at 30 min after oral administration of antimuscarinics.
RESULTS: Intravenous administration of DA-8010 and solifenacin produced dose-dependent decreases on carbachol-induced IVP elevation in mice, with mean ID30 of 0.012 and 0.637 mg/kg, respectively. Oral DA-8010 was effective on bladder for 12 h at 1 mg/ kg and for 24 h at 3 mg/kg. In a PET study, there was a dosedependent decrease in specific binding of [11C](þ)3-MPB in brain regions of mice after i.v. injection of DA-8010 and solifenacin. The doses for 30% receptor occupancy (RO30) of DA-8010 and solifenacin in striatum, cortex, hippocampus, thalamus, and hypothalamus (Table 1) were higher than the ID30 on carbachol-induced IVP increases. In a Y-maze test, oral DA-8010 at 10 and 30 mg/kg had no effect on spontaneous alternation. There was no decrease in the number of total arm entries at any dose level for DA-8010, but it was significantly decreased in mice treated with 100 mg/kg solifenacin.
CONCLUSIONS: DA-8010 is highly selective for the urinary bladder over the brain, demonstrating that DA-8010 at a dose displaying significant effects on the bladder did not bind muscarinic receptors in the mouse brain regions, without any influence on locomotor activity and spatial short-term memory. The wide safety margin of DA-8010 suggests a decreased potential for CNS adverse effects in the treatment of OAB.
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